Ovarian cancer is the fifth commonest malignancy of European women, but occupies first place in the mortality statis-tics for gynaecological malignancies. Effective screening is not yet possible but will potentially be able to significantly improved using the micro-array technique. The postoperative residual tumour represents the most important prog-nostic factor, which underlines the call for centralising the treatment both of the primary cancer and for recurrence of advanced ovarian cancer.The development of new molecular biology substances has already begun and is looking for a significant improvement in treatment outcomes in relation to quality of life and survival rates. Studies have now finally shown the benefit of maintenance therapy with the anti-angiogenesis agent bevacizumab, with a significant improvement in progression-free survival.